(IVVD) Invivyd, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IVVD) Invivyd, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Invivyd, Inc. BCG Matrix is a company-specific strategic tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
PEMGARDA, 2024 EUA
PEMGARDA (pemivibart) is Invivyd’s commercial antibody for COVID-19 pre-exposure prophylaxis, and the U.S. FDA granted it emergency use authorization in 2024. By end-2025, it remained Invivyd’s main growth engine, because it was the company’s key marketed asset and revenue driver. In BCG terms, PEMGARDA fits a "Star" profile: high market potential, but still tied to fast execution and reimbursement uptake.
Only U.S. COVID-19 PrEP antibody
After Evusheld’s withdrawal, PEMGARDA was the only FDA-authorized COVID-19 pre-exposure prophylaxis monoclonal antibody in the U.S., giving Invivyd near-100% share in a very narrow niche. That first-mover position fits a Star profile: high share, but in a market measured by a tiny, immunocompromised patient base. The edge can persist while no direct U.S. rival is authorized.
12 plus years, 40 kg
Invivyd, Inc.’s "12 plus years, 40 kg" Star is aimed at adults and adolescents aged 12 years and older who weigh at least 40 kg, so the addressable pool is narrow but clinically defined. The core users are immunocompromised patients who are unlikely to respond well to vaccination, which supports repeat demand from a high-need segment. That makes this a classic BCG Star when uptake is tied to clear medical need and ongoing protection gaps.
Commercial revenue ramp, 2025
Invivyd’s 2025 value creation is driven by PEMGARDA product sales, and that fits a Star profile in a growing niche. The business is still in scale-up mode, so promotion, access, and distribution are still doing a lot of the work. PEMGARDA remains the main commercial engine, so commercial execution is the key 2025 lever.
- 2025 focus: PEMGARDA sales
- Scale-up phase, not maturity
- Promotion and distribution still matter
- Commercial execution drives growth
Long-acting anti-spike antibody
PEMGARDA is Invivyd, Inc.'s long-acting neutralizing antibody for SARS-CoV-2, built to give prophylaxis that lasts longer than standard short-acting options. Its edge is broad variant coverage and extended protection, which can support demand while COVID-19 keeps mutating. In a niche 2025 market, that keeps this asset in the "Stars" bucket if high-risk prevention stays a priority.
- Long-acting SARS-CoV-2 prophylaxis
- Variant coverage is the key moat
- Best when new strains keep emerging
PEMGARDA Powers Invivyd’s 2025 Growth
PEMGARDA remained Invivyd, Inc.'s Star asset in 2025: the only FDA-authorized COVID-19 pre-exposure prophylaxis monoclonal antibody in the U.S., with near-100% share in a tiny but high-need niche. Its value comes from long-acting variant coverage and repeat use in immunocompromised patients aged 12+ and 40 kg+.
| Star driver | 2025 status |
|---|---|
| PEMGARDA | Main revenue engine |
| U.S. share | Near-100% in niche |
| Market need | High-risk prophylaxis |
What is included in the product
Detailed Word Document
Invivyd, Inc. BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG snapshot of Invivyd, Inc. to spot growth, cash cows, and drag areas at a glance.
Reference Sources
Provides a clear source trail for Invivyd, Inc. that boosts credibility and supports faster, better-informed decisions.
Cash Cows
No mature royalty portfolio
Invivyd, Inc. still does not have a mature royalty or licensing portfolio, so it lacks the steady, low-growth cash cow layer seen in classic BCG models. In fiscal 2025, cash generation was tied mainly to one commercial product, PEMGARDA, not a spread of recurring royalty streams. So the business is still product-dependent, not portfolio-based.
No diversified marketed basket
Invivyd, Inc. does not have a diversified marketed basket: it has 1 approved commercial product, PEMGARDA, so there is no broad base of sales across several diseases.
That leaves revenue highly concentrated in one franchise, which is weak for a BCG "cash cow" profile because stable, repeat cash flow usually comes from multiple mature products.
With only a single marketed asset, cash generation stays fragile and tied to one market, not a durable multi-product engine.
No second blockbuster product
As of year-end 2025, PEMGARDA was still Invivyd, Inc.'s only clear commercial product, so the cash-cow base remained narrow. The company reported 2025 revenue of about $34 million, but that came from a single franchise, not a second blockbuster. A true cash cow portfolio would need another marketed product to add scale and stability.
No mature global scale
Invivyd’s cash-cow base is still narrow because its commercial footprint is almost entirely U.S.-based. In 2025, the Company relied on domestic sales of PEMGARDA and had no disclosed international revenue stream, so it lacked the steadier cash flow that a global launch can bring. That leaves the cash-cow bucket thin, not broad.
- No disclosed non-U.S. sales
- Domestic-only footprint limits stability
- Less diversification, more volatility
Cash still funds R&D
Invivyd, Inc. still uses product receipts to fund R&D, so cash is being recycled into development rather than harvested as surplus. That means the business has not yet reached true cash-cow status; it is still in the build phase, not the cash extraction phase.
- Product cash still supports R&D
- No steady excess cash harvest yet
- Not a mature cash cow
Invivyd Lacks a Cash Cow: One Product, Fragile FY2025 Revenue
Invivyd, Inc. has no true Cash Cows in fiscal 2025: PEMGARDA was the only commercial product, with about $34 million in revenue, so cash flow stayed concentrated and fragile.
There was no mature royalty or licensing stream, and no disclosed non-U.S. sales, so the company lacked the stable, multi-product cash base that defines this BCG bucket.
| Metric | FY2025 |
|---|---|
| Commercial products | 1 |
| Revenue | $34 million |
| Non-U.S. sales | None disclosed |
Preview the Actual Deliverable
Invivyd, Inc. Reference Sources
This preview shows the exact Invivyd, Inc. BCG Matrix report you’ll receive after purchase. You’re viewing the final document, with no demo content or hidden sections. Once purchased, the same file is delivered instantly for your use. It’s ready for editing, printing, or sharing right away.
Dogs
Influenza collaboration, research stage
The Scripps Research collaboration is still discovery-stage, so it targets influenza and beta-coronavirus vaccine ideas, not a marketed product. With no direct product revenue or commercial launch tied to it, it fits the Dogs bucket today. Unless it moves into development and creates cash flow, it stays a low-return research asset for Invivyd, Inc.
Beta-coronavirus vaccine concepts
Beta-coronavirus vaccine concepts at Invivyd, Inc. are still conceptual and long dated, with no disclosed commercial sales or market share as of end-2025. In BCG terms, they sit in the Dogs zone because the asset base is far from revenue scale and needs heavy R&D spend before any payback.
The lack of traction means low near-term return and weak strategic value today. Until these programs move into late-stage human data and a funded path to approval, they remain low-yield options rather than growth engines.
Non-commercial antibody programs
Invivyd, Inc.'s non-commercial antibody programs fit the Dogs box because they are still preclinical or early-stage and have not cleared clinical or regulatory milestones. They consume R&D cash now, but they do not yet produce near-term sales or gross profit. In a company still focused on turning antibody science into approved products, these programs add cost without much current return.
Preclinical assets, no approval path
Invivyd, Inc. preclinical assets fit the Dogs box because preclinical drug work often takes 10+ years and only about 1 in 10 candidates reaches approval. They absorb management time and cash long before any revenue appears, and without a clear regulatory path they stay low-value bets.
- High science risk
- Long time to market
- Cash burn before revenue
- No approval path, no upside
Legacy pipeline spend
Legacy pipeline spend at Invivyd, Inc. can still absorb R&D overhead, lab work, and staff time even when a program is no longer tied to a near-term launch. That makes these older or deprioritized assets a drag on growth, so they fit the dog quadrant.
- Consumes overhead and lab spend
- No near-term product launch
- Drags on growth and cash use
Invivyd’s Precommercial Dogs Burn Cash With No Near-Term Payback
Invivyd, Inc.'s Dogs are still precommercial assets: they generated no disclosed product revenue in 2025 and remain tied to early research, so they burn cash without near-term payback. That keeps them low on BCG value today, even if they could matter later.
| Asset | 2025 status | BCG |
|---|---|---|
| Scripps collaboration | Discovery-stage, no sales | Dog |
| Beta-coronavirus ideas | Conceptual, no market share | Dog |
| Non-commercial antibody programs | Preclinical or early-stage | Dog |
Question Marks
VYD2311, next-gen mAb
VYD2311 is Invivyd, Inc.'s lead next-gen SARS-CoV-2 monoclonal antibody, and it could extend the antiviral franchise if it proves durable against new variants. It sits in the BCG "Question Mark" box because the upside is real, but clinical and FDA success is still unproven. In 2025-2026, the key test is whether it can turn early promise into validated efficacy, safety, and commercial demand.
Broader PEMGARDA label
PEMGARDA’s current FDA EUA covers only COVID-19 pre-exposure prophylaxis in certain immunocompromised patients, so its label is still narrow. Any move into broader use would need new clinical and virology data, not just marketing. That keeps broader label expansion in "question mark" territory for Invivyd, Inc., because the upside is real but still unproven.
Variant coverage candidates
Invivyd’s value hinges on matching each new SARS-CoV-2 wave before rivals do; if a candidate covers a dominant lineage, demand can spike fast. The question-mark profile comes from variant churn, which can reset the market in weeks, not quarters. If coverage stays strong through FY2025-FY2026, this can shift from a niche bet to a star.
Post-exposure or treatment studies
PEMGARDA is a Question Mark here because it is not a treatment product today, and any move into treatment or post-exposure prophylaxis would need new clinical data and FDA support. That upside is real but still uncertain.
Invivyd, Inc. has not shown that PEMGARDA can work after exposure or as a therapy, so this path remains a pipeline option, not a current revenue driver.
- Not a treatment product today
- Needs more data for post-exposure use
- Upside remains uncertain
New infectious-disease indications
Invivyd, Inc.'s platform is still proven in just one area: COVID-19, with one authorized product, PEMGARDA. New infectious-disease targets like RSV or influenza could open a much larger market, but they need fresh clinical proof, more regulatory work, and more spend. Until another indication is validated, these programs stay in the question mark bucket.
- One proven infectious-disease use today.
- New targets could expand the TAM.
- Proof, approval, and spend remain hurdles.
Invivyd’s Upside Is Real, But 2025-2026 Depends on FDA Data and Variants
Invivyd, Inc. keeps its Question Mark status because PEMGARDA’s EUA is still narrow and VYD2311 is not yet proven in patients or at scale. The upside is clear, but 2025-2026 value depends on FDA data, variant coverage, and demand.
| Item | 2025-2026 signal |
|---|---|
| PEMGARDA | Authorized for PrEP only |
| VYD2311 | Lead next-gen asset |
| Key risk | Variant churn |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.